# ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT06904378** · PHASE1,PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 61 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** ONT01
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT06904378
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904378, "ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06904378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*